Ovid Therapeutics Inc Stock News

New York, June 11, Jun 11, 2020 (GLOBE NEWSWIRE via COMTEX) -- New York, June 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the...

When choosing cheap stocks to invest in you don't always have to sacrifice quality. Here are four high-quality companies that are affordable.

Ovid to collaborate with renowned clinical and molecular geneticist expert, Wendy K. Chung, M.D., Ph.D. NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (OVID), a biopharmaceutic

Apellis CEO Cedric François describes what it was like to have Covid-19 and try to manage a company with active clinical trials through a global pandemic.

People tend to negotiate with themselves when faced with difficult situations. I did that with the start of the Covid-19 pandemic.

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced the addition of two partners to its Global Corporate Social Res

Shares have risen by 157% since my 2018 recommendation and by 127% since my September update. Near term events include AACR II presentation (present new ETB pro

Rockefeller Capital Management L.P. lessened its stake in Takeda Pharmaceutical Co Ltd (NYSE:TAK) by 85.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 2,614 sh

Much of the conversation about pharmaceutical stocks rests on the coronavirus, but these high-growth names have potential beyond the pandemic.

Jun 09, 2020 (Market Insight Reports) -- The Ewing Sarcoma Drugs Market report is a compilation of first-hand information, qualitative and quantitative...

NEW YORK, June 08, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced findings from two new interim analyses of data from the Phase 3 H

NEW YORK, June 04, Jun 04, 2020 (GLOBE NEWSWIRE via COMTEX) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing...

Company to host first webinar on Wednesday, June 17, to review OV935 (soticlestat) development program for rare developmental and epileptic encephalopathies (DEE) NEW YORK,.